Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 16/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 13/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 1.00 |
| ▸ | KDM1A | O60341 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250888 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL13784491 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL13784487 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL13784490 | 0.99 | HDAC3 (0.97) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL13784488 | 0.99 | HDAC3 (0.97) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL13751929 | 0.89 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL8246005 | 0.80 | HDAC6 (0.66) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL12913969 | 0.79 | KDM1A (0.73) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL8254153 | 0.79 | HDAC1 (0.67) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL10045196 | 0.78 | KCNH2 (0.70) | HDAC1HDAC8HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182019-A1 | Histone deacetylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2006113606-A2 | HISTONE DEACETYLASE INHIBITORS | JOHNS HOPKINS UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182019-A1 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC8 8/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.